EQS-News : Relief and AdVita Sign Binding Term Sheet for Relief to Acquire All Shares of AdVita to Expand Scope of Development of Inhaled Formulation of Aviptadil

EQS Group-News: RELIEF THERAPEUTICS Holdings AG / Key word(s): Mergers & Acquisitions 
Relief and AdVita Sign Binding Term Sheet for Relief to Acquire All Shares of AdVita to Expand Scope of Development of 
Inhaled Formulation of Aviptadil 
2021-01-20 / 07:00 
=---------------------------------------------------------------------------------------------------------------------- 
Relief and AdVita Sign Binding Term Sheet for Relief to Acquire All Shares of AdVita to Expand Scope of Development of 
Inhaled Formulation of Aviptadil 
Geneva, Switzerland, and Gundelfingen, Germany, January 20, 2021 - RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: 
RLFTF) ("Relief"), a biopharmaceutical company with its lead compound RLF-100^TM (Aviptadil) in advanced clinical 
development to treat severe COVID-19 patients, and AdVita Lifescience GmbH ("AdVita"), a Germany-based, privately held 
pharmaceutical company developing effective products and strategies to improve the treatment and diagnosis of rare lung 
diseases, today announced the companies have signed a binding term sheet for Relief to acquire all shares of AdVita in 
exchange for EUR 25 million of Relief common shares, plus possible future contingent milestone payments of up to EUR 20 
million. The closing of the transaction is subject to customary closing conditions as well as legal and securities 
regulatory approvals and is expected to occur in Q2 2021. 
Amongst the AdVita assets being acquired in this transaction, Relief will gain further pending intellectual property 
rights that may cover RLF-100^TM inhaled formulation specifications^and the potential application of inhaled Aviptadil 
in the treatment of Acute Respiratory Distress Syndrome (ARDS) and Checkpoint Inhibitor-induced Pneumonitis (CIP). 
"AdVita's intellectual property around inhaled formulations of Aviptadil and its team's expertise with Aviptadil will 
be invaluable as we move forward with the development of the inhaled formulation of RLF-100(TM) for the treatment of 
COVID-19-related ARDS, as well as other potential lung disease indications, such as pulmonary Sarcoidosis and Chronic 
Beryllium Disease," said Jack Weinstein, CFO and Treasurer of Relief. "We look forward to initiating the development of 
inhaled RLF-100(TM) in Europe within the coming months for COVID-19 patients using inhaled Aviptadil. Furthermore, we 
plan to re-start a clinical development program for RLF-100^TM in pulmonary Sarcoidosis later this year." 
Under the terms of the agreement, Relief will advance a EUR 2 million convertible secured loan to AdVita. The first 
tranche of EUR 1 million will be advanced concurrent with the execution of the binding term sheet and the second 
tranche of EUR 1 million upon the successful conclusion of Relief's phase 2b/3 clinical trial of intravenous RLF-100^TM 
in the treatment of critical COVID-19 patients with respiratory failure. Top-line data from this trial are expected at 
the end of January or early February of this year. 
Dorian Bevec, Ph.D., CSO of AdVita, commented: "We are excited to combine our specific expertise in inhaled 
formulations of Aviptadil with Relief's comprehensive scientific catalog of the compound and its uses in respiratory 
diseases." 
### 
ABOUT RELIEF 
Relief focuses primarily on clinical-stage programs based on molecules of natural origin (peptides and proteins) with a 
history of clinical testing and use in human patients or a strong scientific rationale. Currently, Relief is 
concentrating its efforts on developing new treatments for respiratory disease indications. Its lead drug candidate 
RLF-100^TM (Aviptadil), synthetic vasoactive intestinal peptide (VIP), is being developed in collaboration with 
NeuroRx, Inc. and is currently being investigated in two placebo-controlled U.S. phase 2b/3 clinical trials in 
respiratory deficiency due to COVID-19. RLF-100^TM is believed to be the first COVID-19 therapeutic to demonstrate the 
ability to block replication of the SARS-CoV-2 virus in human lung cells and monocytes, while also preventing synthesis 
of cytokines in the lung. Since July 2020, severe COVID-19 patients have been treated with RLF-100^TM under U.S. FDA 
Emergency Use Investigational New Drug (IND) authorization and Expanded Access Protocol authorization for the treatment 
of respiratory failure in COVID-19. Relief also holds a patent issued in the United States and various other countries 
covering potential formulations of RLF-100^TM. 
RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB 
under the symbol RLFTF. 
Follow us on LinkedIn 
ABOUT ADVITA LIFESCIENCE GMBH 
AdVita Lifescience GmbH was founded in 2019 with the purpose of developing effective products and strategies to improve 
the therapy and diagnosis of rare lung diseases. 
CONTACT                                                FOR MEDIA/INVESTOR INQUIRES: 
RELIEF THERAPEUTICS Holding AG                         MC Services AG 
Raghuram (Ram) Selvaraju, Ph.D., MBA                   Anne Hennecke / Brittney Sojeva 
Chairman of the Board                                  Mail: [e-mail] 
Mail: [e-mail]                   Tel.: [phone] 
www.relieftherapeutics.com 
AdVita Lifescience GmbH 
Wolfgang Hoppe 
Chief Executive Officer 
[e-mail] 
www.advita-lifescience.com 

Disclaimer: This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of RELIEF THERAPEUTICS Holding AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. RELIEF THERAPEUTICS Holding AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. -----------------------------------------------------------------------------------------------------------------------

End of Media Release -----------------------------------------------------------------------------------------------------------------------

Language:     English 
Company:      RELIEF THERAPEUTICS Holdings AG 
              Avenue de Sécheron 15 
              1202 Genève 
              Switzerland 
E-mail:       [e-mail] 
Internet:     https://relieftherapeutics.com 
ISIN:         CH0100191136 
Listed:       SIX Swiss Exchange 
EQS News ID:  1161800 
 
End of News   EQS Group News Service 
=---------- 

(MORE TO FOLLOW) Dow Jones Newswires

January 20, 2021 01:01 ET (06:01 GMT)